Beryllium: A modern industrial hazard

Annual Review of Public Health

Volumn 28, Issue , 2007, Pages 259-277

  Kreiss, Kathleen ^a   Day, Gregory A ^a   Schuler, Christine R ^a  

^a NATIONAL INSTITUTE FOR OCCUPATIONAL SAFETY AND HEALTH   (United States)

Author keywords

Berylliosis; Dermal exposure; Genetics; Sensitization

Indexed keywords

ALLOY;

BERYLLIOSIS; CLINICAL RESEARCH; CONFERENCE PAPER; GENETIC SCREENING; GENOTYPE ENVIRONMENT INTERACTION; HEALTH HAZARD; HUMAN; LUNG GRANULOMA; MEDICAL TECHNOLOGY; NONHUMAN; OCCUPATIONAL HAZARD; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; RISK MANAGEMENT; SEMICONDUCTOR; SENSITIZATION; SKIN PROTECTION; SPACE; TELECOMMUNICATION; TRANSGENIC MOUSE;

AIR POLLUTANTS, OCCUPATIONAL; ANIMALS; BERYLLIOSIS; BERYLLIUM; HUMANS; INDUSTRY; MICE; PREVALENCE; SAFETY MANAGEMENT;

EID: 34249659968     PISSN: 01637525     EISSN: None     Source Type: Book Series    
DOI: 10.1146/annurev.publhealth.28.021406.144011     Document Type: Conference Paper

References (75)

1. Baur X, Chen Z, Liebers V. 1998. Exposure-response relationships of occupational inhalative allergens. Clin. Exp. Allergy 28(5):537-44
2. Cummings KJ, Deubner DC, Day GA, Henneberger PK, Kitt M, et al. 2007. Enhanced preventive program at a beryllium ceramics plant reduces beryllium sensitization among new workers. Occup. Environ. Med. J. doi: 10.1136/oem.2006.027987
3. Curtis GH. 1951. Cutaneous hypersensitivity due to beryllium: a study of thirteen cases. AMA Arch. Dermatol. Syph. 64(4):470-82
4. Day GA, Dufresne A, Stefaniak AB, Schuler CR, Stanton ML, et al. 2006. Exposure pathway assessment at a copper-beryllium alloy facility. Ann. Occup. Hyg. doi:10.1093/annhyg/me1041
5. Day GA, Hoover MD, Stefaniak AB, Dickerson RM, Peterson EJ, et al. 2005. Bioavailability of beryllium oxide particles: an in vitro study in the murine J774A.1 macrophage cell line model. Exp. Lung. Res. 31(3):341-60
6. Day GA, Stefaniak AB, Weston A, Tinkle SS. 2006. Beryllium exposure: dermal and immunological considerations. Int. Arch. Occup. Environ. Health 79(2):161-64
7. Dep. Energy. 2001. Energy Employees Occupational Illness Compensation Program Act of 2000. 20 C.F.R. Part 30
8. DeNardi JM, VanOrdstrand HS, Carmody MG. 1949. Acute dermatitis and pneumonitis in beryllium workers: Review of 406 cases in eight year period with follow-up on recoveries. Ohio State Med. J. 45:567-75
9. Deubner DC, Goodman M, Iannuzzi J. 2001. Variability, predictive value, and uses of the beryllium blood lymphocyte proliferation test (BLPT): preliminary analysis of the ongoing workforce survey. Appl. Occup. Environ. Hyg. 16(5):521-26
10. Deubner D, Kelsh M, Shum M, Maier L, Kent M, Lau E. 2001. Beryllium sensitization, chronic beryllium disease, and exposures at a beryllium mining and extraction facility. Appl. Occup. Environ. Hyg. J. 16(5):579-92
11. Eisenbud M. 1982. Origins for the standards of control of beryllium disease (1947-1949). Environ. Res. 27(1):79-88
12. Eisenbud M. 1998. The standard for control of chronic beryllium disease. Appl. Occup. Environ. Hyg. J. 13(1):25-31
13. Eisenbud M, Lisson J. 1983. Epidemiologic aspects of beryllium-induced nonmalignant lung disease: a 30-year update. J. Occup. Med. 25(3):196-202
14. Eisenbud M, Wanta RC, Dustan C, Steadman LT, Harris WB, Wolf BS. 1949. Non-occupational berylliosis. J. Indust. Hyg. Toxicol. 31:282-94
15. Fed. Regist. 2000. To prohibit discrimination in federal employment based on genetic information. Exec. Order 13145 65(28):6877-80
16. Fontenot AP, Maier LA, Canavera SJ, Hendry-Hofer TB, Boguniewicz M, et al. 2002. Beryllium skin patch testing to analyze T cell stimulation and granulomatous inflammation in the lung. J. Immunol. 168(7):3627-34
17. Gaulding J. 1995. Race, sex and genetic discrimination in insurance: What's fair? Cornell Law Rev. 80:1646-94
18. Gelman I. 1936. Poisoning by vapors of beryllium oxyfluoride. J. Indust. Hyg. Toxicol. 18:371-79
19. Hall RH, Scott JK, Laskin S, Stroud CA, Stokinger HE. 1950. Acute toxicity of inhaled beryllium: observations correlating toxicity with the physicochemical properties of beryllium oxide dust. Arch. Ind. Hyg. Occup. Med. 2(1):25-48
20. Hardy HL, Rabe EW, Lorch S. 1967. United States, Beryllium Case Registry (1952-1966). Review of its methods and utility. J. Occup. Med. 9(6):271-76
21. Hardy HL, Tabershaw IR. 1946. Delayed chemical pneumonitis in workers exposed to beryllium compounds. J. Indust. Hyg. Toxicol. 28:197-211
22. Henneberger PK, Cumro D, Deubner D, Kent M, McCawley M, Kreiss K. 2001. Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int. Arch. Occup. Environ. Health 74:167-76
23. Henneberger PK, Goe SK, Miller WE, Groce DW. 2004. Industries in the United States with airborne beryllium exposure and the numbers of workers potentially exposed. J. Occup. Environ. Hyg. 1:648-69
24. Hoover MD, Finch GL, Mewhinney JA, Eidson AF. 1990. Release of aerosols during sawing and milling of beryllium metal and beryllium alloys. Appl. Occup. Environ. Hyg. J. 5(11):787-91
25. Hyslop F, Palmes ED, Alford WC, Monaco AR, Fairhall LT. 1943. The toxicology of beryllium. Natl. Inst. Health Bull. 181. Washington, DC: US Public Health Serv.
26. Keefer CM. 1999. Bridging the gap between life insurance and consumer in the genetic testing era: the RF proposal. Ind. Law J. 74:1375-97
27. Kitt M, Henneberger PK, Deubner DC, Schuler C, McCanlies E, Kreiss K. 2003. Cumulative incidence of chronic beryllium disease in a ceramics factory cohort, abstract #59721. Presented at Annu. Meet. Am. Public Health Assoc., 131st, San Francisco
28. 3. Am. J. Ind. Med. 30(1):16-25
29. Kreiss K, Mroz MM, Zhen B, Martyny JW, Newman LS. 1993. The epidemiology of beryllium sensitization and disease in nuclear workers. Am. Rev. Respir. Dis. 148:985-91
30. Kreiss K, Mroz M, Zhen B, Wiedemann H, Barna B. 1997. Risks of beryllium disease related to work processes at a metal, alloy, and oxide production plant. Occup. Environ. Med. 54(8):605-12
31. Kreiss K, Newman LS, Mroz MM, Campbell PA. 1989. Screening blood test identifies subclinical beryllium disease. J. Occup. Med. 31(7):603-8
32. Kreiss K, Wasserman SL, Mroz MM, Newman LS. 1993. Beryllium disease screening in the ceramics industry: blood lymphocyte test performance and exposure-disease relations. J. Occup. Med. 35(3):267-74
33. Langmuir AD. 1963. The surveillance of communicable diseases of national importance. N. Engl. J. Med. 268:182-91
34. Levy BS, Wegman DH, Halperin WE. 2000. Recognizing occupational disease and injury. In Occupational Health: Recognizing and Preventing Work-Related Disease and Injury, ed. BS Levy, DH Wegman, 4:99-122. Philadelphia: Lippincott Williams & Wilkins
35. Lieben J, Metzner F. 1959. Epidemiological findings associated with beryllium extraction. Am. Ind. Hyg. Assoc. J. 29:494-9
36. Maier LA, McGrath DS, Sato H, Lympany P, Welsh K, et al. 2003. Influence of MHC Class II in susceptibility to beryllium sensitization and chronic beryllium disease. J. Immunol. 171(12):6910-18
37. Maier LA, Newman LS. 1998. Beryllium disease. In Environmental and Occupational Medicine, ed. WN Rom, 3:1021-35. Philadelphia: Lippincott-Raven
38. Gln69 and chronic beryllium disease and beryllium sensitization. Am. J. Ind. Med. 46(2):95-103
39. McCawley MA, Kent MS, Berakis MT. 2001. Ultrafine beryllium number concentration as a possible metric for chronic beryllium disease risk. Appl. Occup. Environ. Hyg. J. 16(5):631-38
40. Muller-Quernheim J, Gaede KI, Fireman E, Zissel G. 2006. Diagnoses of chronic beryllium disease within cohorts of sarcoidosis patients. Eur. Respir. J. 27(6):1190-95
41. Naumann BD, Sargent EV, Starkman BS, Fraser WJ, Becker GT, Kirk GD. 1996. Performance-based exposure control limits for pharmaceutical active ingredients. Am. Ind. Hyg. Assoc. J. 57(1):33-42
42. Newman LS, Kreiss K. 1992. Nonoccupational beryllium disease masquerading as sarcoidosis: identification by blood lymphocyte proliferative response to beryllium. Am. Rev. Respir. Dis. 145(5):1212-14
43. Newman LS, Mroz MM, Balkissoon R, Maier LA. 2005. Beryllium sensitization progresses to chronic beryllium disease: a longitudinal study of disease risk. Am. J. Respir. Crit. Care Med. 171(1):54-60
44. Newman LS, Mroz MM, Maier LA, Daniloff EM, Balkissoon R. 2001. Efficacy of serial medical surveillance for chronic beryllium disease in a beryllium machining plant. J. Occup. Environ. Med. 43(3):231-37
45. Occup. Safety Health Adm. 1975. Occupational exposure to beryllium. 29 C.F.R. Part 1910
46. Oldershaw PJ. 2001. Control banding - a practical approach to judging control methods for chemicals. J. Prevent. Med. 9(4):52-58
47. Petsonk EL, Wang ML, Lewis DM, Siegel PD, Husberg BJ. 2000. Asthma-like symptoms in wood product plant workers exposed to methylene diphenyl diisocyanate. Chest 119(4):1183-93
48. Richeldi L, Kreiss K, Mroz M, Zhen B, Tartoni P, Saltini C. 1997. Interaction of genetic and exposure factors in the prevalence of berylliosis. Am. J. Ind. Med. 32(4):337-40
49. Richeldi L, Sorrentino R, Saltini C. 1993. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease. Science 262(5131):242-44
50. Rosenman K, Hertzberg V, Rice C, Reilly MJ, Aronchick J, et al. 2005. Chronic beryllium disease and sensitization at a beryllium processing facility. Environ. Health Perspect. 113(10):1366-72
51. Rossman MD, Stubbs J, Lee CW, Argyris E, Magira E, Monos D. 2002. Human leukocyte antigen class II amino acid epitopes: susceptibility and progression markers for beryllium hypersensitivity. Am. J. Respir. Crit. Care Med. 165(6):788-94
52. Sackett HM, Maier LA, Silveira LJ, Mroz MM, Ogden L, et al. 2004. Beryllium medical surveillance at a former nuclear weapons facility during cleanup operations. J. Occup. Environ. Med. 46(9):953-61
53. Saltini C, Richeldi L, Losi M, Amicosante M, Voorter C, et al. 2001. Major histocompatibility locus genetic markers of beryllium sensitization and disease. Eur. Respir. J. 18(4):677-84
54. Saltini C, Winestock K, Kirby M, Pinkston P, Crystal RG. 1989. Maintenance of alveolitis in patients with chronic beryllium disease by beryllium-specific helper T cells. N. Engl. J. Med. 320(17):1103-9
55. Schuler CR, Kent MS, Deubner DC, Berakis MT, McCawley M, et al. 2005. Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. Am. J. Ind. Med. 47(3):195-205
56. Shilen J, Kippenhaver FB, Cleland JG, Lutz LR, Vought VM. 1954. Beryllium extraction, reduction, and alloy fabrication: an engineering study covering ten years' experience. Indust. Med. Surg. 23(7):291-99
57. Silverstein M. 1994. Analysis of medical screening and surveillance in 21 Occupational Safety and Health Administration standards: support for a generic medical surveillance standard. Am. J. Ind. Med. 26(3):283-95
58. 2+ in proteins and influence of the dielectric environment. J. Phys. Chem. B 109(37):17757-61
59. Snyder JA, Weston A, Tinkle SS, Demchuk E. 2003. Electrostatic potential on human leukocyte antigen: implications for putative mechanism of chronic beryllium disease. Environ. Health Perspect. 111(15):1827-34
60. Stange AW, Hilmas DE, Furman FJ. 1996. Possible health risks from low exposure to beryllium. Toxicology 111:213-24
61. Stange AW, Furman FJ, Hilmas DE. 2004. The beryllium lymphocyte proliferation test: relevant issues in beryllium health surveillance. Am. J. Ind. Med. 46(5):453-62
62. Stange AW, Hilmas DE, Furman FJ, Gatliffe T. 2001. Beryllium sensitization and chronic beryllium disease at a former nuclear weapons facility. Appl. Occup. Environ. Hyg. J. 16(3):405-17
63. Stanton ML, Henneberger PK, Kent MS, Deubner DC, Kreiss K, Schuler CR. 2006. Sensitization and chronic beryllium disease among workers in copper-beryllium distribution centers. J. Occup. Environ. Med. 48(2):204-11
64. Stefaniak AB, Day GA, Hoover MD, Breysse PN, Scripsick RC. 2006. Differences in dissolution behavior in a phagolysosomal simulant fluid for single-component and multi-component materials associated with beryllium sensitization and chronic beryllium disease. Toxicol. in Vitro 20(1):82-95
65. Stefaniak AB, Guilmette RA, Day GA, Hoover MD, Breysse PN, et al. 2005. Characterization of phagolysosomal simulant fluid for study of beryllium aerosol particle dissolution. Toxicol. in Vitro 19(1):123-34
66. Stefaniak AB, Hoover MD, Day GA, Dickerson RM, Peterson EJ, et al. 2004. Characterization of physicochemical properties of beryllium aerosols associated with prevalence of chronic beryllium disease. J. Environ. Monit. 6(6):523-32
67. Stefaniak AB, Hoover MD, Dickerson RM, Peterson EJ, Day GA, et al. 2003. Surface area of respirable beryllium metal, oxide, and copper alloy aerosols and implications for assessment of exposure risk of chronic beryllium disease. Am. Ind. Hyg. Assoc. J. 64(3):297-305
68. Tinkle SS, Antonini JM, Rich BA, Roberts JR, Sahnen R, et al. 2003. Skin as a route of exposure and sensitization in chronic beryllium disease. Environ. Health Perspect. 111(9):1202-208
69. VanOrdstrand HS, Hughes R, Carmody MG. 1943. Chemical pneumonia in workers extracting beryllium oxide: report of three cases. Cleve. Clin. Quart. 10(2):10-18
70. VanOrdstrand HS, Hughes R, DeNardi JM, Carmody MG. 1945. Beryllium poisoning. JAMA 129:1084-90
71. Wang Z, Farris GM, Newman LS, Shou Y, Maier LA, et al. 2001. Beryllium sensitivity is linked to HLA-DP genotype. Toxicology 165(1):27-38
72. Wang Z, White PS, Petrovic M, Tatum OL, Newman LS, et al. 1999. Differential susceptibilities to chronic beryllium disease contributed by different Glu69 HLA-DPB1 and -DPA1 alleles. J. Immunol. 163(3):1647-53
73. Welch L, Ringen K, Bingham E, Dement J, Takaro T, et al. 2004. Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am. J. Ind. Med. 46(3):207-18
74. Weston A, Ensey J, Kreiss K, Keshava C, McCanlies E. 2002. Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for chronic beryllium disease. Am. J. Ind. Med. 41(6):457-65
75. Weston W, Snyder J, McCanlies EC, Schuler CR, Andrew ME, et al. 2005. Immunogenetic factorsin beryllium sensitization and chronic beryllium disease. Mutat. Res. 592(1-2):68-78